Roche's Amylin-Based Weight Loss Drug Delivers 10.7% Reduction in Phase 2 but Falls Short of Eli Lilly's Rival, Sending Zealand Pharma Shares Down 32%
Petrelintide met its primary endpoint with placebo-like tolerability, but a dose ceiling and a seven-point efficacy gap to Lilly's eloralintide raise questions about its standalone future.
Overview
Roche and its partner Zealand Pharma announced positive Phase 2 results for petrelintide, an investigational long-acting amylin analog for chronic weight management, on March 5, 2026. Participants in the ZUPREME-1 trial achieved up to 10.7 percent mean body weight reduction at 42 weeks, compared with 1.7 percent for placebo, according to Roche’s press release. The drug met its primary endpoint with a tolerability profile that Roche described as comparable to placebo. However, the results fell meaningfully short of the bar set by Eli Lilly’s competing amylin drug eloralintide, which posted roughly 16 percent placebo-controlled weight loss in its own Phase 2 trial, as reported by BioSpace. Zealand Pharma shares dropped 32 percent in premarket trading following the announcement.
What We Know
The ZUPREME-1 trial enrolled 493 adults with overweight or obesity across 33 sites in the United States, Poland, and Romania, with a mean baseline BMI of 37 kg/m2, according to Roche. The study population was 53 percent female with a mean age of 48 years. Participants received once-weekly subcutaneous injections of petrelintide at one of five dose levels or placebo, with doses escalated every four weeks.
The trial met its primary endpoint at week 28, demonstrating statistically significant weight reduction across all five treatment arms compared with placebo (p<0.001). Weight loss continued through week 42, reaching up to 10.7 percent from baseline at the highest effective dose.
The tolerability data stood out as particularly strong. At the maximally effective dose, the dropout rate due to adverse events was 4.8 percent for petrelintide compared with 4.9 percent for placebo, according to Roche. There were zero cases of vomiting in the maximally effective dose group, and 70 percent of participants at that dose experienced no gastrointestinal side effects at all, as reported by MedCity News. Ninety-eight percent of participants reached their maintenance dose.
Petrelintide works by activating amylin receptors, which restores sensitivity to the satiety hormone leptin and induces a sense of fullness. This mechanism is distinct from the GLP-1 receptor agonists such as semaglutide and tirzepatide that currently dominate the obesity market.
The Competitive Problem
Despite the positive primary endpoint, the market reaction was sharply negative. The roughly 9 percent placebo-controlled weight loss fell well below the approximately 16 percent placebo-controlled weight loss that Eli Lilly’s eloralintide achieved in its Phase 2 study at 48 weeks, according to Lilly’s announcement.
William Blair analysts stated that the seven-percentage-point gap between the two amylin drugs was “too large to attribute to enrolled population alone,” as reported by BioSpace. The analysts also identified a dose ceiling effect in the petrelintide data: higher doses did not produce additional weight loss, creating what they called a “challenging situation” since the favorable tolerability profile would theoretically support higher dosing but with no expected benefit.
Zealand Pharma shares fell 32 percent to $247.80 in premarket trading on the day of the announcement, according to BioSpace.
What We Don’t Know
Several uncertainties remain. The trial showed that female participants achieved notably greater weight reductions than males, but Roche has not disclosed the gender-stratified figures. The company also has not released the specific week-28 primary endpoint data, only describing it as statistically significant.
It is unclear whether the combination of petrelintide with CT-388, a dual GLP-1/GIP receptor agonist that Roche acquired through its $2.7 billion purchase of Carmot Therapeutics, could close the efficacy gap with standalone eloralintide or combination GLP-1 approaches. Roche has stated that a Phase 2 combination trial will begin later in 2026, according to MedCity News.
Results from ZUPREME-2, which evaluates petrelintide in patients with obesity or overweight and type 2 diabetes, are expected in the second half of 2026. It remains to be seen whether petrelintide performs differently in a metabolically distinct population.
Analysis
The petrelintide results illustrate a tension at the heart of the emerging amylin drug class: exceptional tolerability does not automatically translate into competitive efficacy. In the current obesity drug landscape, where GLP-1 agonists routinely deliver 15 to 25 percent weight loss, a standalone 10.7 percent reduction may not be sufficient to carve out significant market share.
William Blair analysts suggested that petrelintide’s best application may be as a maintenance therapy, leveraging its placebo-like safety profile for long-term use, as reported by MedCity News. This positioning would represent a meaningful shift from the blockbuster monotherapy narrative that initially drove investor enthusiasm around amylin-based drugs.
Roche’s combination strategy with CT-388 may ultimately prove more consequential than the monotherapy data. If pairing petrelintide’s amylin mechanism with GLP-1/GIP activation can approach or exceed the weight loss delivered by tirzepatide while maintaining a superior side-effect profile, the drug could find a durable role. For now, however, Eli Lilly holds the early advantage in the amylin race, with plans to advance eloralintide into late-stage trials in 2026.